The Growing Myopia Epidemic

Myopia prevalence has reached epidemic proportions globally, with projections suggesting that 50% of the world's population will be myopic by 2050. This represents not just a refractive error, but a significant public health concern due to increased risks of sight-threatening complications including retinal detachment, glaucoma, and myopic maculopathy.

Evidence-Based Treatment Options

1. Orthokeratology (Ortho-K)

Overnight corneal reshaping with specialized rigid gas permeable lenses has shown 40-60% reduction in axial elongation. Recent studies demonstrate sustained efficacy over 5+ years with excellent safety profiles when proper fitting protocols and hygiene are maintained.

2. Low-Dose Atropine Therapy

Low-dose atropine (0.01%, 0.025%, 0.05%) has emerged as the most prescribed myopia control treatment worldwide. The LAMP2 study demonstrated dose-dependent efficacy, with 0.05% showing optimal balance between efficacy (67% reduction in progression) and minimal side effects.

3. Multifocal Soft Contact Lenses

Dual-focus and extended depth-of-focus designs create peripheral myopic defocus, slowing axial growth by 30-50%. MiSight 1 day lenses (FDA-approved for myopia control) show consistent results across diverse populations.

4. Myopia Control Spectacle Lenses

Novel spectacle designs incorporating HALT technology or DIMS show 30-40% efficacy. These provide excellent options for children unable or unwilling to wear contact lenses.

Treatment Selection Algorithm

Choose treatment based on:

• Age: Younger children (6-8) often start with spectacles or atropine
• Progression Rate: Rapid progressors may benefit from combination therapy
• Parent/Child Preference: Consider lifestyle, compliance factors
• Refractive Error: Higher myopes may benefit from ortho-k

Monitoring Protocol

Comprehensive monitoring should include:

• Axial length measurements every 6 months (primary outcome)
• Cycloplegic refraction annually
• Corneal topography for ortho-k patients
• Slit lamp examination at each visit

Business Case for Myopia Management

Implementing a myopia management specialty offers significant practice benefits:

• High-margin specialty services with strong patient retention
• Builds reputation as forward-thinking, evidence-based practice
• Creates multi-year patient relationships (average 5-7 year treatment course)
• Strong parent satisfaction drives referrals

Getting Started

Begin by attending specialized training courses, obtaining necessary diagnostic equipment (IOL Master or Lenstar for axial length), and developing parent education materials. Start with 2-3 treatment modalities and expand as expertise grows.